The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Volume 124 , Issue 14
Showing 1-6 articles out of 6 articles from the selected issue
Committee Report
Seminar for Medical Education
Original Articles
  • Naoya Yamazaki, Shigeru Sakamoto
    2014 Volume 124 Issue 14 Pages 3159-3170
    Published: December 20, 2014
    Released: December 25, 2014
    During treatment with anti-epidermal growth factor receptor antibody, skin disorders are considered major adverse drug reactions. Clinical features of skin disorders during panitumumab (Pmab) treatment for wild-type KRAS gene unresectable, advanced or recurrent colorectal cancer were analyzed as a post hoc analysis of a post-marketing surveillance study for Pmab. Information was collected during clinical courses for 10 months, or until discontinuation of Pmab for any reason. Among 3,085 patients, dermatitis acneiform occurred in 69.9% of the patients, paronychia in 24.2%, dry skin in 21.7%, and pruritus in 4.8%. Among the patients who experienced skin disorders, 6.9% of the patients withdrew from panitumumab therapy because of skin disorders. Topical corticosteroids, oral antibiotics, or emollients were usually administered for treatment of skin disorders. Approximately 80% of the patients with these adverse events recovered or were recovering. The incidence of dermatitis acneiform was significantly higher in males, patients who were <65 years who had heavier body weight, or who took a higher dose per 1 m2 of body surface area.
    Download PDF (847K)